Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Clinical importance of long non‑coding RNA LINC00460 expression in EGFR‑mutant lung adenocarcinoma.

Nakano Y, Isobe K, Kobayashi H, Kaburaki K, Isshiki T, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, Homma S, Kishi K.

Int J Oncol. 2019 Nov 25. doi: 10.3892/ijo.2019.4919. [Epub ahead of print]

PMID:
31789388
2.

Activation of mucosal-associated invariant T cells in the lungs of sarcoidosis patients.

Matsuyama H, Isshiki T, Chiba A, Yamaguchi T, Murayama G, Akasaka Y, Eishi Y, Sakamoto S, Homma S, Miyake S.

Sci Rep. 2019 Sep 12;9(1):13181. doi: 10.1038/s41598-019-49903-6.

3.

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Isshiki T, Sakamoto S, Homma S.

Medicina (Kaunas). 2019 May 20;55(5). pii: E172. doi: 10.3390/medicina55050172. Review.

4.

Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation.

Nishikawa M, Takeda Y, Isomura N, Tanigawa T, Nanasato M, Tsukahara K, Kimura K, Takayama T, Hirayama A, Kato M, Nishikawa H, Nishimura Y, Isshiki T, Yokoi H; j-CHIPS group.

J Atheroscler Thromb. 2019 May 14. doi: 10.5551/jat.48934. [Epub ahead of print]

5.

Development of Propionibacterium acnes-associated Sarcoidosis During Etanercept Therapy.

Isshiki T, Matsuyama H, Sakamoto S, Honma N, Mikami T, Shibuya K, Eishi Y, Homma S.

Intern Med. 2019 May 15;58(10):1473-1477. doi: 10.2169/internalmedicine.2086-18. Epub 2019 Jan 10.

6.

Reply: Using Intravascular Ultrasound in Patients With Acute Coronary Syndrome: Characterizing Attenuated Plaque Is (Im)possible?

Hibi K, Kozuma K, Kimura K, Isshiki T.

JACC Cardiovasc Interv. 2018 Dec 24;11(24):2545-2546. doi: 10.1016/j.jcin.2018.10.028. No abstract available.

PMID:
30573065
7.

Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y12 inhibitors compared with clopidogrel.

Guo CG, Chen L, Chan EW, Cheung KS, Isshiki T, Wong ICK, Leung WK.

Aliment Pharmacol Ther. 2019 Jan;49(1):7-19. doi: 10.1111/apt.15059. Epub 2018 Dec 2. Review.

PMID:
30506985
8.

Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression.

Isshiki T, Isobe K, Tochigi N, Sunakawa M, Nakamura Y, Shibuya K, Sakamoto S, Takai Y, Homma S.

Case Rep Oncol. 2018 Oct 31;11(3):688-692. doi: 10.1159/000493187. eCollection 2018 Sep-Dec.

9.

Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study.

Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators.

Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13575. [Epub ahead of print]

10.

A Randomized Study of Distal Filter Protection Versus Conventional Treatment During Percutaneous Coronary Intervention in Patients With Attenuated Plaque Identified by Intravascular Ultrasound.

Hibi K, Kozuma K, Sonoda S, Endo T, Tanaka H, Kyono H, Koshida R, Ishihara T, Awata M, Kume T, Tanabe K, Morino Y, Tsukahara K, Ikari Y, Fujii K, Yamasaki M, Yamanaka T, Kimura K, Isshiki T; VAMPIRE 3 Investigators.

JACC Cardiovasc Interv. 2018 Aug 27;11(16):1545-1555. doi: 10.1016/j.jcin.2018.03.021. Epub 2018 Aug 1.

11.

Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.

Shimizu H, Sakamoto S, Isshiki T, Furuya K, Kurosaki A, Homma S.

PLoS One. 2018 May 24;13(5):e0196558. doi: 10.1371/journal.pone.0196558. eCollection 2018.

12.

Effect of QRS Morphology and Duration on Clinical Outcomes After Cardiac Resynchronization Therapy - Analysis of Japanese Multicenter Registry.

Oka T, Inoue K, Tanaka K, Hirao Y, Isshiki T, Kimura T, Nobuyoshi M, Shizuta S, Arita T, Fujii S, Iwakura K, Fujii K, Ando K.

Circ J. 2018 Jun 25;82(7):1813-1821. doi: 10.1253/circj.CJ-17-1383. Epub 2018 Apr 7.

13.

Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study.

Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators.

Diabetes Care. 2018 Jun;41(6):1275-1284. doi: 10.2337/dc17-2224. Epub 2018 Apr 6.

PMID:
29626074
14.

Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis.

Sugino K, Shimizu H, Nakamura Y, Isshiki T, Matsumoto K, Homma S.

J Thorac Dis. 2018 Feb;10(2):899-908. doi: 10.21037/jtd.2018.01.56.

15.

Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A historically controlled study.

Sakamoto S, Shimizu H, Isshiki T, Sugino K, Kurosaki A, Homma S.

Respir Investig. 2018 Mar;56(2):136-143. doi: 10.1016/j.resinv.2017.10.004. Epub 2017 Dec 16.

PMID:
29548651
16.

Optimal Specifications for the Advanced Pedestrian Legform Impactor.

Isshiki T, Antona-Makoshi J, Konosu A, Takahashi Y.

Stapp Car Crash J. 2017 Nov;61:373-395.

PMID:
29394446
17.

Cutting Edge: Anti-TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice.

Isshiki T, Akiba H, Nakayama M, Harada N, Okumura K, Homma S, Miyake S.

J Immunol. 2017 Dec 1;199(11):3733-3737. doi: 10.4049/jimmunol.1700059. Epub 2017 Oct 23.

18.

Surface morphology and dislocation characteristics near the surface of 4H-SiC wafer using multi-directional scanning transmission electron microscopy.

Sato T, Orai Y, Suzuki Y, Ito H, Isshiki T, Fukui M, Nakamura K, Schamp CT.

Microscopy (Oxf). 2017 Oct 1;66(5):337-347. doi: 10.1093/jmicro/dfx022.

PMID:
29016923
19.

The Activities of Daily Living after an Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Koyama K, Sakamoto S, Isshiki T, Shimizu H, Kurosaki A, Homma S.

Intern Med. 2017 Nov 1;56(21):2837-2843. doi: 10.2169/internalmedicine.7875-16. Epub 2017 Sep 25.

20.

Add-on Antiplatelet Effects of Eicosapentaenoic Acid With Tailored Dose Setting in Patients on Dual Antiplatelet Therapy.

Hosogoe N, Ishikawa S, Yokoyama N, Kozuma K, Isshiki T.

Int Heart J. 2017 Aug 3;58(4):481-485. doi: 10.1536/ihj.16-430. Epub 2017 Jul 14.

21.

Duration of reverse remodeling response to cardiac resynchronization therapy: Rates, predictors, and clinical outcomes.

Oka T, Inoue K, Tanaka K, Toyoshima Y, Isshiki T, Kimura T, Nobuyoshi M, Shizuta S, Arita T, Fujii S, Iwakura K, Fujii K, Ando K.

Int J Cardiol. 2017 Sep 15;243:340-346. doi: 10.1016/j.ijcard.2017.05.058. Epub 2017 May 12.

PMID:
28545852
22.

Crystallographic and electronic properties of AlCrN films that absorb visible light.

Tatemizo N, Imada S, Miura Y, Nishio K, Isshiki T.

AIP Adv. 2017 May 10;7(5):055306. doi: 10.1063/1.4983491. eCollection 2017 May.

23.

Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.

Furuya K, Sakamoto S, Shimizu H, Sekiya M, Kinoshita A, Isshiki T, Sugino K, Matsumoto K, Homma S.

Respir Med. 2017 May;126:93-99. doi: 10.1016/j.rmed.2017.03.026. Epub 2017 Mar 29.

24.

Four-Dimensional Computed Tomography-Based Finite Element Modeling of the Behavior of the Right Coronary Artery.

Nakagawa Y, Hayashi H, Izumi C, Kondo H, Tamura T, Enomoto S, Amano M, Nishimura S, Tanaka Y, Isshiki T, Watanabe H, Hanafusa K, Yamazaki Y, Nakamura T, Eguchi K.

Circ J. 2017 Jun 23;81(7):1059-1061. doi: 10.1253/circj.CJ-16-1132. Epub 2017 Jan 28. No abstract available.

25.

STEM and HRTEM studies of accumulated deposits on human tooth surface.

Wakasa M, Eshita Y, Nakanishi K, Isobe T, Manago K, Okamoto M, Isshiki T.

Microsc Res Tech. 2017 May;80(5):511-524. doi: 10.1002/jemt.22825. Epub 2017 Jan 25.

PMID:
28124499
26.

Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies.

Nishikawa M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Miyazaki S, Ikeda Y, Nakamura M, Tanaka Y, Saito S.

Cardiovasc Interv Ther. 2017 Apr;32(2):93-105. doi: 10.1007/s12928-016-0452-7. Epub 2017 Jan 17. Review.

PMID:
28097639
27.

Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease.

Takura T, Tachibana K, Isshiki T, Sumitsuji S, Kuroda T, Mizote I, Ide S, Nanto S.

Cardiovasc Interv Ther. 2017 Apr;32(2):127-136. doi: 10.1007/s12928-016-0401-5. Epub 2016 May 26.

PMID:
27230087
28.

Higher Hemoglobin A1c After Discharge Is an Independent Predictor of Adverse Outcomes in Patients With Acute Coronary Syndrome - Findings From the PACIFIC Registry.

Noguchi K, Sakakibara M, Asakawa N, Tokuda Y, Kamiya K, Yoshitani T, Oba K, Miyauchi K, Nishizaki Y, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Origasa H, Isshiki T, Morino Y, Daida H, Tsutsui H; PACIFIC investigators.

Circ J. 2016 Jun 24;80(7):1607-14. doi: 10.1253/circj.CJ-15-1126. Epub 2016 May 19.

29.

Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients.

Nagatsuka K, Miyata S, Kada A, Kawamura A, Nakagawara J, Furui E, Takiuchi S, Taomoto K, Kario K, Uchiyama S, Saito K, Nagao T, Kitagawa K, Hosomi N, Tanaka K, Kaikita K, Katayama Y, Abumiya T, Nakane H, Wada H, Hattori A, Kimura K, Isshiki T, Nishikawa M, Yamawaki T, Yonemoto N, Okada H, Ogawa H, Minematsu K, Miyata T.

Thromb Haemost. 2016 Aug 1;116(2):356-68. doi: 10.1160/TH15-11-0864. Epub 2016 Apr 21.

PMID:
27098431
30.

Hyper-Response to Clopidogrel in Japanese Patients Undergoing Transcatheter Aortic Valve Implantation.

Watanabe Y, Kozuma K, Ishikawa S, Hosogoe N, Isshiki T.

Int Heart J. 2016;57(2):190-7. doi: 10.1536/ihj.15-290. Epub 2016 Mar 11.

31.

A Feasibility Study of Virtual Reality Exercise in Elderly Patients with Hematologic Malignancies Receiving Chemotherapy.

Tsuda K, Sudo K, Goto G, Takai M, Itokawa T, Isshiki T, Takei N, Tanimoto T, Komatsu T.

Intern Med. 2016;55(4):347-52. doi: 10.2169/internalmedicine.55.5275. Epub 2016 Feb 15.

32.

Fine structure of tooth enamel in the yellowing human teeth: SEM and HRTEM studies.

Wakasa M, Nakanishi K, Manago K, Isobe T, Eshita Y, Okamoto M, Isshiki T.

Microsc Res Tech. 2016 Jan;79(1):14-22. doi: 10.1002/jemt.22600. Epub 2015 Nov 13.

PMID:
26768788
33.

The clinical characteristics and prognosis of lesions with in-stent eccentric tissue proliferation and strong signal attenuation detected by optical coherence tomography.

Suzuki N, Kozuma K, Kyono H, Nakaya H, Nishide S, Mitsui M, Nara Y, Kawashima H, Nomura T, Yamamoto H, Sasajima Y, Kondo F, Isshiki T.

Cardiovasc Interv Ther. 2016 Jul;31(3):210-7. doi: 10.1007/s12928-015-0369-6. Epub 2015 Nov 25.

PMID:
26608163
34.

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.

Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Tanaka Y, Saito S.

J Cardiol. 2016 Jul;68(1):29-36. doi: 10.1016/j.jjcc.2015.07.019. Epub 2015 Oct 29.

35.

Impact of the automatic rounding-off function of the computerized physician order entry system on the ordering time and dose dispersion of chemotherapeutic drugs in regimens for hematologic malignancies.

Tsuda K, Kimura Y, Tanimoto T, Takaba Y, Okubo K, Ishii T, Takahashi Y, Itokawa T, Isshiki T, Takei N, Kobayashi K, Nakagawa M, Komatsu T.

Int J Med Inform. 2016 Jan;85(1):76-9. doi: 10.1016/j.ijmedinf.2015.10.006. Epub 2015 Oct 24.

PMID:
26520235
36.

[Case Report; Influenza vaccination-associated acute lung injury: two cases report].

Hirasawa Y, Kono C, Yamada Y, Maemura K, Takeshima H, Makita K, Yamaguchi Y, Isshiki T, Suzuki M, Yamaguchi T.

Nihon Naika Gakkai Zasshi. 2015 Jul 10;104(7):1457-9. Japanese. No abstract available.

PMID:
26513964
37.

No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: A post hoc analysis.

Nishikawa M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Miyazaki S, Ikeda Y, Nakamura M, Takita A, Saito S; PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with Acute Coronary Syndrome undergoing percutaneous coronary intervention) Investigators.

Thromb Res. 2015 Nov;136(5):947-54. doi: 10.1016/j.thromres.2015.09.014. Epub 2015 Sep 21.

38.
39.

Primary Antiphospholipid Syndrome Associated with Diffuse Alveolar Hemorrhage and Pulmonary Thromboembolism.

Isshiki T, Sugino K, Gocho K, Furuya K, Shimizu H, Sekiya M, Ohata T, Wada T, Isobe K, Sakamoto S, Takai Y, Homma S.

Intern Med. 2015;54(16):2029-33. doi: 10.2169/internalmedicine.54.4058. Epub 2015 Aug 15.

40.

Usefulness of Everolimus-Eluting Coronary Stent Implantation in Patients on Maintenance Hemodialysis.

Ikari Y, Kyono H, Isshiki T, Ishizuka S, Nasu K, Sano K, Okada H, Sugano T, Uehara Y.

Am J Cardiol. 2015 Sep 15;116(6):872-6. doi: 10.1016/j.amjcard.2015.05.061. Epub 2015 Jun 24.

PMID:
26219496
41.

ICOS promotes group 2 innate lymphoid cell activation in lungs.

Kamachi F, Isshiki T, Harada N, Akiba H, Miyake S.

Biochem Biophys Res Commun. 2015 Aug 7;463(4):739-45. doi: 10.1016/j.bbrc.2015.06.005. Epub 2015 Jun 4.

PMID:
26049110
42.

Impact of Arterial Access Route on Bleeding Complications in Japanese Patients Undergoing Percutaneous Coronary Intervention- Insight From the PRASFIT Trial.

Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nishikawa M, Miyazaki S, Tanaka Y, Nakamura M; PRASFIT-ACS and PRASFIT-Elective Investigators.

Circ J. 2015;79(9):1928-37. doi: 10.1253/circj.CJ-15-0276. Epub 2015 Jun 4.

43.

Clinical and angiographic outcomes of paclitaxel-eluting coronary stent implantation in hemodialysis patients: A prospective multicenter registry: The OUCH-TL study (outcome in hemodialysis of TAXUS Liberte).

Kozuma K, Otsuka M, Ikari Y, Uehara Y, Yokoi H, Sano K, Tanabe K, Hibi K, Yamane M, Ishiwata S, Ohta H, Yamauchi Y, Suematsu N, Nakayama M, Inoue N, Kyono H, Suzuki N, Isshiki T.

J Cardiol. 2015 Dec;66(6):502-8. doi: 10.1016/j.jjcc.2015.03.008. Epub 2015 Apr 4.

44.

Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention.

Kimura T, Isshiki T, Ogawa H, Yokoi H, Yamaguchi T, Ikeda Y.

J Atheroscler Thromb. 2015;22(6):557-69. doi: 10.5551/jat.26013. Epub 2014 Dec 27.

45.

Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.

Nakamura M, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Ikeda Y, Saito S.

Int J Cardiol. 2015 Mar 1;182:541-8. doi: 10.1016/j.ijcard.2015.01.026. Epub 2015 Jan 8.

46.

Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study.

Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S.

Respiration. 2015;89(3):201-7. doi: 10.1159/000369828. Epub 2015 Feb 5.

47.

Quantitative optical coherence tomography analysis for late in-stent restenotic lesions.

Fu Q, Suzuki N, Kozuma K, Miyagawa M, Nomura T, Kawashima H, Shiratori Y, Ishikawa S, Kyono H, Isshiki T.

Int Heart J. 2015;56(1):13-7. doi: 10.1536/ihj.14-136. Epub 2014 Dec 11.

48.

Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.

Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S; PRASFIT-Elective Investigators.

Circ J. 2014;78(12):2926-34. Epub 2014 Oct 21.

49.

HPV vaccination for cervical cancer prevention is not cost-effective in Japan.

Isshiki T.

Asian Pac J Cancer Prev. 2014;15(15):6177-80.

50.

Intriguing transmission electron microscopy images observed for perpendicularly oriented cylindrical microdomains of block copolymers.

Ohnogi H, Isshiki T, Sasaki S, Sakurai S.

Nanoscale. 2014 Sep 21;6(18):10817-23. doi: 10.1039/c4nr02074j. Epub 2014 Aug 11.

PMID:
25111849

Supplemental Content

Loading ...
Support Center